Literature DB >> 31710714

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.

Stephen P H Alexander1, Doriano Fabbro2, Eamonn Kelly3, Alistair Mathie4, John A Peters5, Emma L Veale4, Jane F Armstrong6, Elena Faccenda6, Simon D Harding6, Adam J Pawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6.   

Abstract

The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14752. Enzymes are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31710714      PMCID: PMC6844577          DOI: 10.1111/bph.14752

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  2 in total

1.  Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).

Authors:  Kenneth D Rice; Naing Aay; Neel K Anand; Charles M Blazey; Owen J Bowles; Joerg Bussenius; Simona Costanzo; Jeffry K Curtis; Steven C Defina; Larisa Dubenko; Stefan Engst; Anagha A Joshi; Abigail R Kennedy; Angie I Kim; Elena S Koltun; Julie C Lougheed; Jean-Claire L Manalo; Jean-Francois Martini; John M Nuss; Csaba J Peto; Tsze H Tsang; Peiwen Yu; Stuart Johnston
Journal:  ACS Med Chem Lett       Date:  2012-04-09       Impact factor: 4.345

2.  Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.

Authors:  Stefano Crosignani; Catherine Jorand-Lebrun; Gordon Campbell; Adeline Prêtre; Tania Grippi-Vallotton; Anna Quattropani; Gwenaelle Bouscary-Desforges; Agnes Bombrun; Marc Missotten; Yves Humbert; Christèle Frémaux; Mikaël Pâquet; Kamel El Harkani; Charles G Bradshaw; Christophe Cleva; Nada Abla; Hamina Daff; Olivier Schott; Pierre-André Pittet; Jean-François Arrighi; Marilène Gaudet; Zoë Johnson
Journal:  ACS Med Chem Lett       Date:  2011-10-10       Impact factor: 4.345

  2 in total
  231 in total

1.  Inhibition of heparanase protects against pancreatic beta cell death in streptozotocin-induced diabetic mice via reducing intra-islet inflammatory cell infiltration.

Authors:  Wen-Yu Song; Xiao-Han Jiang; Ying Ding; Yan Wang; Ming-Xuan Zhou; Yun Xia; Chen-Yu Zhang; Chong-Chong Yin; Chen Qiu; Kai Li; Peng Sun; Xiao Han
Journal:  Br J Pharmacol       Date:  2020-08-19       Impact factor: 8.739

Review 2.  Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Authors:  Claudia Penna; Ioanna Andreadou; Manuela Aragno; Christophe Beauloye; Luc Bertrand; Antigone Lazou; Ines Falcão-Pires; Robert Bell; Coert J Zuurbier; Pasquale Pagliaro; Derek J Hausenloy
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

Review 3.  Interventions in the B-type natriuretic peptide signalling pathway as a means of controlling chronic itch.

Authors:  Jianghui Meng; Weiwei Chen; Jiafu Wang
Journal:  Br J Pharmacol       Date:  2020-02-12       Impact factor: 8.739

4.  Differential hepatoprotective role of the cannabinoid CB1 and CB2 receptors in paracetamol-induced liver injury.

Authors:  Patricia Rivera; Antonio Vargas; Antoni Pastor; Anna Boronat; Antonio Jesús López-Gambero; Laura Sánchez-Marín; Dina Medina-Vera; Antonia Serrano; Francisco Javier Pavón; Rafael de la Torre; Ekaitz Agirregoitia; María Isabel Lucena; Fernando Rodríguez de Fonseca; Juan Decara; Juan Suárez
Journal:  Br J Pharmacol       Date:  2020-04-15       Impact factor: 8.739

5.  Low-concentration DMSO accelerates skin wound healing by Akt/mTOR-mediated cell proliferation and migration in diabetic mice.

Authors:  Wei Guo; Wei Qiu; Xiang Ao; Weiqiang Li; Xiao He; Luoquan Ao; Xueting Hu; Zhan Li; Ming Zhu; Donglin Luo; Wei Xing; Xiang Xu
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

6.  Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation.

Authors:  Ana Carolina Moreira Souza; Andrea Grabe-Guimarães; Jader Dos Santos Cruz; Artur Santos-Miranda; Charlotte Farah; Liliam Teixeira Oliveira; Alexandre Lucas; Franck Aimond; Pierre Sicard; Vanessa Carla Furtado Mosqueira; Sylvain Richard
Journal:  Br J Pharmacol       Date:  2020-08-24       Impact factor: 8.739

7.  Blockade of angiotensin AT1 receptors prevents arterial remodelling and stiffening in iron-overloaded rats.

Authors:  Helbert Gabriel Fidelis; Jandinay Gonzaga Alexandre Mageski; Susana Curry Evangelista Goes; Tatiani Botelho; Vinicius Bermond Marques; Renata Andrade Ávila; Leonardo Dos Santos
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

8.  Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.

Authors:  Zinnia P Parra-Guillen; Antonio Fontanellas; Lei Jiang; Daniel Jericó; Paolo Martini; Diego Vera-Yunca; Marjie Hard; Lin T Guey; Iñaki F Troconiz
Journal:  Br J Pharmacol       Date:  2020-04-14       Impact factor: 8.739

9.  First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

Authors:  Priska Kaufmann; Marion Ort; Georg Golor; Rüdiger Kornberger; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

10.  Metabolic effects of carvedilol through β-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts.

Authors:  Berna Güven; Zümra Kara; Arzu Onay-Beşikci
Journal:  Br J Pharmacol       Date:  2020-11-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.